# The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

> **NCT05042336** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 49 (estimated)

## Conditions studied

- Carrelizumab Plus Lenvatinib Combined With TACE
- Borderline Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** camrelizumab/lenvatinib combined with TACE

## Key facts

- **NCT ID:** NCT05042336
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042336, "The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05042336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*